Roche's pharmaceutical sales declined 2% in local currencies to CHF 37.1 billion ($38.7 billion). Sales in international markets
(i.e., Asia Pacific, excluding Japan, Central and Eastern Europe, the Middle East, Africa, Central Asia, Indian subcontinent,
Latin America, and Canada) were CHF 9.2 billion ($9.6 billion), an 8% increase in local currencies, representing 25% of Roche's
pharmaceutical sales, a level commensurate with pharmaceutical sales to Western Europe. Roche noted strong growth in Latin
America (20%), led by Brazil and Venezuela, and solid growth in the Asia-Pacific region (8%), led by China and Taiwan. Roche's
bestsellers internationally were the anticancer therapy Herceptin (trastuzumab) and the autoimmune drug MabThera/Rituxan (rituximab)
with sales of CHF 1.5 billion ($1.6 billion) and CHF 1.4 billion ($1.5 billion), respectively.
Roche's US pharmaceutical sales, its largest market with a 38% share, fell 1% to CHF 14.1 billion ($14.7 billion). Pharmaceutical
sales to Western Europe, which accounted for 25% of its 2010 pharmaceutical sales, declined 5% to CHF 9.5 billion ($9.9 billion).
Pharmaceutical sales to Japan, which accounted for 12% of Roche's sales in 2010, fell 12% to CHF 4.3 billion ($4.5 billion).
AstraZeneca reported strong growth in emerging markets, which offset declining US sales. AstraZeneca had 2010 pharmaceutical
sales of $33.27 billion, in part reflecting a 7% decline in the US to $13.73 billion. Sales to emerging markets increased
15% to $5.20 billion, which represented the first time that the company exceeded sales growth of $5 billion in emerging markets.
Revenue in China increased 28% to $1.05 billion, and sales to other emerging Asia-Pacific countries increased 7% to $890 million.
Sales to other emerging markets (i.e., Brazil, India, Mexico, Russia, Turkey, and other countries) increased 20% to $2.10
billion. Sales to emerging markets increased 6% yo $1.17 billion. In contrast, pharmaceutical sales to Western Europe increased
only 2% to $9.25 billion, and sales to the established rest-of-world markets (i.e., Canada, Japan, Australia, and New Zealand)
increased 7% to $5.18 billion. AstraZeneca's top-selling therapeutic areas in emerging markets were cardiovascular ($1.74
billion), gastrointestinal ($874 million), oncology ($843 million), respiratory ($762 million), and neuroscience ($650 million).
Bristol-Myers Squibb had net sales of $19.48 billion in 2010, a 4% increase compared with 2009, when it reported sales of
$18.81 billion. The US accounted for approximately 65% or $12.61 billion of its 2010 sales. At a UBS Healthcare conference
in September 2010, Beatrice Calaza, senior vice-president of commercial operations and president of global commercialization
for Europe and emerging markets, emphasized that the company's emerging-market growth strategy is aligned to the company's
overall biopharmaceutical strategy and is focused on five emerging markets: China, Brazil, Russia, Turkey, and India. BMS
historically has had modest sales to emerging markets. No single country outside the US contributed more than 10% of the company's
total net sales in 2009, 2008, or 2007. The combined net sales in emerging markets approximated 4% of total net sales in 2009
and 2008 and 3% in 2007.
Abbott had worldwide pharmaceutical sales of $19.89 billion in 2010. International sales represented 56% of its pharmaceuticals
sales, or $11.15 billion, and US sales accounted for 44% or $8.74 billion. International pharmaceutical sales increased 28.3%
in 2010 compared with 12.2% growth for US pharmaceutical sales, in part due to the company's acquisition of the pharmaceutical
business of Solvay Pharmaceuticals in February 2010 and the domestic formulation business of India's Piramal Healthcare Solutions
in September 2010.
Other companies showed mixed results. Johnson & Johnson reported pharmaceutical sales of $22.40 billion, a 0.6% decline compared
with 2009 sales. US pharmaceutical sales decreased 4% to $12.52 billion, and international sales increased 4.2% to $9.88 billion.
In 2010, Eli Lilly reported global pharmaceutical revenue of $21.68 billion, accounting for the majority of its total sales
of $23.10 billion, which included sales in its animal-health business of $1.39 billion. Overall sales increased 6% in 2010
compared with 2009. US revenues increased 5% to $12.87 billion, and revenues outside the US increased 7% to $10.21 billion.
Merck & Co. reported pharmaceutical sales (human health and consumer healthcare products) in 2010 of $39.81 billion and did
not break out sales to emerging markets in its 2010 earnings release.
Patricia Van Arnum is a senior editor at Pharmaceutical Technology, 485 Route One South, Bldg F, First Floor, Iselin, NJ 08830tel. 732.346.3072, firstname.lastname@example.org